Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in ...
SPRING, Texas, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., presented results from studies done in a mouse model of triple negative breast cancer with the company’s newest anti-cancer compound IRX5010, an agonist of the retinoic acid nuclear …